Brain Research
October 1, 1990
Christopher J. Schmidt, Christine K. Black, Gina M. Abbate et al.
132 citations
Methylenedioxymethamphetamine (MDMA) produced a significant hyperthermia in rats which was antagonized in a competitive manner by the selective 5-HT2 antagonist, MDL 11,939. The 5-HT antagonist also blocked MDMA-induced neurotoxicity as assessed by the decline in regional 5-HT concentrations observed 1 week later. These two effects of MDL 11,939 were dissociated at higher doses of MDMA where...
Annals of the New York Academy of Sciences
October 1, 1990
Errol B. de Souza, George Battaglia, Thomas R. Insel
54 citations
In summary, the data from both neurochemical and neuroanatomical studies demonstrate widespread and long-lasting degeneration of serotonin neurons in brain without any major or consistent effects on catecholamine neurons following in vivo administration of MDMA in both rats and rhesus monkeys. A detailed examination of the parameters involved in the neurotoxic and neurodegenerative effects of...
Annals of the New York Academy of Sciences
October 1, 1990
Milt Teitler, Sigrun Leonhardt, Nathan M. Appel et al.
33 citations
The data presented herein appear to strongly implicate the brain 5HT2 receptor as the site-of-action of the hallucinogenic PIAs and LSD. If so, this discovery represents a major step in understanding the molecular pharmacology of hallucinogenic drugs. Using radioactive hallucinogenic drugs, detailed properties of brain 5HT2 receptors indicating the interaction of 5HT2 receptors with GTP-binding...
Annals of the New York Academy of Sciences
October 1, 1990
Mark E. Molliver, Urs V. Berger, Laura A. Mamounas et al.
252 citations
The cytotoxic effects of amphetamine derivatives were studied by immunocytochemistry to identify the cellular compartments affected by these drugs, to obtain morphologic evidence of neuronal degeneration, and to assess the potential for regeneration. The substituted amphetamines, MDA, MDMA, PCA, and fenfluramine, all release serotonin and cause acute depletion of 5-HT from most axon terminals...
Journal of Pharmacology and Experimental Therapeutics
August 1, 1990
M. Hiramatsu, Y. Kumagai, S. Unger et al.
The in vitro conversion of (+)-3,4-methylenedioxymethamphetamine and (-)-3,4-methylenedioxymethamphetamine to the corresponding catecholamine, 3,4-dihydroxymethamphetamine (N-methyl-alpha-methyldopamine), by rat liver microsomes was examined. Metabolite formation was monitored after short-term incubations using high-performance liquid chromatography-electrochemical detection to determine...
Journal of Pharmacology and Experimental Therapeutics
August 1, 1990
C. Callaway, Lauren L. Wing, Mark A. Geyer et al.
Methylenedioxymethamphetamine (MDMA) is a phenylethylamine with novel mood-altering properties in humans. MDMA shares the dopamine-releasing properties of amphetamine but has been found to be a more potent releaser of serotonin (5-HT). The present study undertook to determine the relative roles of dopamine and 5-HT release in MDMA-induced locomotor hyperactivity. S-(+)MDMA produced...
Journal of Pharmacology and Experimental Therapeutics
July 1, 1990
J. T. Winslow, T. Insel
3,4-Methylenedioxymethamphetamine (MDMA) has previously been shown to destroy serotonin terminals in the rat brain. Despite profound and prolonged loss of serotonin innervation, long-term behavioral effects of MDMA have not previously been reported. In this study, we monitored the short- and long-term effects of MDMA administration on the ultrasonic isolation call of the rat pup. At 30 to 60...
Neuropharmacology
July 1990
Kenji Hashimoto, Tsuyoshi Goromaru
The effects of 3,4-methylenedioxymethamphetamine (MDMA) on the in vivo binding of [3H]paroxetine, a potent and selective 5-hydroxytryptamine (5-HT; serotonin) uptake inhibitor, in the brain of the mouse were studied. The distribution of radioactivity in the brain of the mouse, after intravenous administration of [3H]paroxetine, was significantly altered by pretreatment with MDMA (15 mg/kg,...
Journal of Labelled Compounds and Radiopharmaceuticals
April 1, 1990
Kenji Hashimoto, Katsumi Hirai, Tsuyoshi Goromaru
AbstractThe synthesis of 3,4‐methylenedioxymethamphetamine(MDMA), a serotonergic neurotoxin, labeled with tritium is described. Labeling was accomplished by N‐alkylation of the free base of the corresponding desmethyl compound using [3H]methyl iodide. The compound was purified by preparative HPLC. The radiochemical yield was about 60% based on [3H]methyl iodide. The radiochemical purity was...
Pharmacology, Biochemistry, and Behavior
March 1990
J P Zacny, R M Virus, William L. Woolverton
The effects of (+-)-3,4-methylenedioxymethamphetamine (MDMA) (0.62-20.0 mg/kg), (+)-methamphetamine (MA) (0.62-5.0 mg/kg) and (+/-)-3,4-methylenedioxyamphetamine (MDA) (0.62-5.0 mg/kg) on milk intake in rats were determined before and during a period of repeated daily administration of MDMA. Experimental sessions consisted of 15-min access to a sweetened milk solution each day, 5 days a week....